Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months
Executive Summary
The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City